Publication:
Bisphosphonate-osteoclasts: Changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients

dc.contributor.authorJobke, Björn (24177922100)
dc.contributor.authorMilovanovic, Petar (25927301300)
dc.contributor.authorAmling, Michael (7005175450)
dc.contributor.authorBusse, Björn (26533959100)
dc.date.accessioned2025-07-02T12:32:37Z
dc.date.available2025-07-02T12:32:37Z
dc.date.issued2014
dc.description.abstractOsteoclasts are unique cells capable of bone resorption and therefore have become a major target in osteoporosis treatment strategies. Bisphosphonates suppress bone turnover via interference with the internal enzymatic cell system of osteoclasts leading to cytoskeletal disruption. This mechanism found its clinical relevance in reducing bone resorption, stabilizing bone mass and reducing fracture risk in osteoporosis patients. However, knowledge about specific in vivo changes in osteoclast cell morphology and function is still insufficient. We examined osteoclasts in 23 paired bone biopsies from osteoporosis patients (18 males, 5 females; age: 52.6 ± 11.5. yrs) under nitrogen-containing bisphosphonate administration with a mean treatment duration of three years. Formalin-fixed, undecalcified sections were assessed by qualitative and quantitative bone histomorphometry, where the osteoclast morphology, nuclei, distribution, location as well as resorption parameters were investigated to obtain information about cell function and viability. After three years of treatment, resorption parameters decreased significantly while the number of osteoclasts remained unchanged. Out of 23 patients, nine developed previously termed "giant-osteoclasts" with increased size, numerous nuclei (>. 10 nuclei/Oc) and oftentimes detachment from the bone surface. These cells frequently had pycnotic nuclei and other morphological signs suggestive of osteoclast apoptosis. Characteristic large-sized osteoclasts were uniquely found in patients treated with nitrogen-containing bisphosphonates, thus being clearly distinguishable from giant-osteoclasts in other bone disorders such as Paget disease, secondary hyperparathyroidism or osteopetrosis. The resorption indices of large-sized osteoclasts, specifically the eroded perimeter and erosion depth, revealed significantly reduced values but not an entirely inhibited resorption capability. Bisphosphonate-osteoclasts' viability and affinity to bone seem significantly disturbed while the apoptotic process may be prolonged for a yet unknown period of time in favor of maintaining a low bone turnover. © 2013 Elsevier Inc.
dc.identifier.urihttps://doi.org/10.1016/j.bone.2013.10.024
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84888036721&doi=10.1016%2fj.bone.2013.10.024&partnerID=40&md5=302df7181d4ca124bc1ea0cbd1366c25
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/13684
dc.subjectBisphosphonate-osteoclasts
dc.subjectBisphosphonates
dc.subjectBone histomorphometry
dc.subjectOsteoclasts
dc.subjectOsteoporosis
dc.titleBisphosphonate-osteoclasts: Changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients
dspace.entity.typePublication

Files